Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewisa are differentiation antigens immunogenic in human melanoma

Cancer

Volumn 79, Issue 9, 1997, Pages 1686-1697

  Ravindranath, Mepur H ^a,b   Amiri, Amir A ^a   Bauer, Philip M ^a   Kelley, Mark C ^a   Essner, Richard ^a   Morton, Donald L ^a  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

anti sialyl Lewis(x) immunoglobulin M; anti sialyl Lewisa immunoglobulin M; endothelial selectin ligands; immunogenicity; immunotherapy; melanoma; melanoma cell vaccine; melanoma differentiation antigens; sialy Lewisa; sialyl Lewis(x)

Indexed keywords

BCG VACCINE; IMMUNOGLOBULIN M; LIGAND; MELANOMA ANTIGEN; MELANOMA VACCINE; SELECTIN;

ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CELL SUSPENSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; BIOPSY; CANCER VACCINES; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIUM, VASCULAR; GANGLIOSIDES; HUMANS; LIGANDS; MELANOCYTES; MELANOMA; MICE; OLIGOSACCHARIDES; SELECTINS; TUMOR CELLS, CULTURED;

EID: 0030910463     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970501)79:9<1686::AID-CNCR8>3.0.CO;2-A     Document Type: Article

References (39)

1. x. Science 1990; 250:1130-2.
2. x determinant on myeloid and tumor cells. Science 1990; 250:1132-5.
3. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, et al. Monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentose II. J Biol Chem 1982; 257:14365-9.
4. Anostario M, Li SH, Huang K. A ligand binding assay for E-selectin. Anal Biochem 1994; 221:317-22.
5. x with MUC-1 apomucin in a pancreatic cancer cell line. Cancer Res 1995; 55:3659-63.
6. Groves RW, Allen MH, Ross L, Ahsan G, Jonathan N, Backer WN, et al. Expression of selectin ligands by cutaneous squamous cell carcinoma. Am J Pathol 1993; 143:1220-5.
7. Takada M, Yamamoto M, Hasegawa Y, Saitoh Y. Endothelial leukocyte adhesion molecule-1-mediated vasoinvasion of human pancreatic adenocarcinoma. J Surg Res 1995; 59:653-7.
8. x related antigens in adenocarcinomas of lung. Histopathology 1993; 22:549-55.
9. Kawai T, Suzuki M, Kase L, Ozeki Y. Expression of carbohydrate antigens in human pulmonary adenocarcinoma. Cancer 1993; 72:1581-7.
10. x and proliferating cell nuclear antigen in stage I non-small cell lung cancer: relation to postoperative recurrence. Cancer 1994; 73:1177-83.
11. x antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 1993; 53:3632-7.
12. Narita T, Funahashi H, Satoh Y, Watanabe T, Sakamoto J, Takagi H. Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer 1993; 71:3044-53.
13. x and related carbohydrate antigens in the prostate. Hum Pathol 1995; 26:735-9.
14. a to adhesion of human cancer cells to vascular endothelium. Cancer Res 1993; 53:354-61.
15. Ogawa J, Sano A, Inoue H, Koide S. Expression of Lewis-related antigen and prognosis in stage I non-small cell lung cancer. Ann Thorac Surg 1994; 59:412-5.
16. a as a target for bispecific antibody-directed adoptive tumor immunotherapy. Immunol Lett 1995; 44:35-40.
17. Hanai N, Shitara K, Yoshida H. Distribution of a squamous cell lung carcinoma-associated antigen, KA-32, in human tissues and sera defined by monoclonal antibody KM-32. Cancer Res 1986; 46:5206-10.
18. x-negative melanoma cell line binds to E-selectin but not to P-selectin. Cancer Res 1987; 47:1267-72.
19. a expression and tumor progression in melanoma. Cancer Res 1995; 55:1748-51.
20. Hanai N, Shitara K, Furuya A, Yoshida H, Dohi T, Nudelman E, et al. Detailed characterization of reactivities of anti-gastric cancer monoclonal antibodies to carbohydrate antigen. Anticancer Res 1990; 10:1579-86.
21. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma: detection and characterization of mouse monoclonal antibody. J Exp Med 1982; 155:1133-47.
22. 3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol 1986; 102:688-96.
23. Mermelstein N. Is that what you mean? J Immunol Methods 1987; 103:141.
24. Morton DL, Foshag LJ, Hoon DBS, Nizze JA, Wanek LA, Chang DC, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1994; 216:463-82.
25. Ravindranath MH, Amid AA, Bauer PM. A sensitive cell suspension ELISA [cs-ELISA] for measuring the density of cell-surface ganglioside and carbohydrate antigens. In: Townsend T, Hotchkiss A. Techniques in Glycobiology. New York: Marcel Dekker, Inc., 1996:137-65.
26. Ravindranath MH, Bauer PM, Cornillez-Ty C, Garcia J, Morton DL. Quantitation of the density of cell-surface carbohydrate antigens on cancer cells with a sensitive cell-suspension ELISA. J Immunol Methods 1996; 197:51-67.
27. Ravindranath MH, Ravindranath RMH, Morton DL, Graves MC. Factors affecting the fine specificity and sensitivity of serum anti-ganglioside antibodies in ELISA. J Immunol Methods 1994; 169:257-72.
28. Yokoyama M, Trams EG, Brady RO. Immunochemical studies with gangliosides. J Immunol 1963; 90:372-80.
29. Ravindranath MH, Morton DL, Irie RF. Attachment of monophosphoryl lipid A (MPL) to cells and liposomes augments antibody response to membrane-bound gangliosides. J Autoimmun 1994; 7:803-16.
30. Morton DL, Ravindranath MH, Irie RF. Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. Prog Brain Res 1994; 101:251-75.
31. 2. Proc Natl Acad Sci USA 1989; 83:8694-8.
32. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory response at tumor sites. J Clin Oncol 1986; 6:1636-48.
33. Reisfeld RA, Schrappe M. Current status and future perspectives of chemoimmunoconjugates for the treatment of cancer. In: Borrebaeck CAD, Larrick JW. Therapeutic monoclonal antibodies. New York: Stockton Press, 1990:57-74.
34. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145:147-66.
35. Ravindranath MH, Morton DL. Active specific immunotherapy with vaccines. In: Holland JF, Frei E III, Bast RC, Kufe DW, Morton DL, Weichselbaum RR. Cancer Medicine. 4th edition. Baltimore: Williams and Wilkins, 1997:1179-98.
36. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34-42.
37. Ravindranath MH, Brazeau SM, Morton DL. Effect of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside. Experientia 1994; 50:648-53.
38. Davis AC, Roux KH, Shulman MJ. On the structure of polymeric IgM. Eur J Immunol 1988; 18:1001-12.
39. Jones RC, Kelley M, Gupta RK, Nizze JA, Yee R, Leopoldo Z, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996; 3:437-45.